Author:
Chawla Prerna K.,Nanday Shweta R.,Dherai Alpa J.,Soman Rajeev,Lokhande Rohan V.,Naik Prasad R.,Ashavaid Tester F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference28 articles.
1. VFEND® I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [US physician prescribing information] New York (NY) Roerig Division of Pfizer Inc; revised 2008 Mar [cited 2008 Sep 3]. http://media.pfizer.com/files/products/uspi_vfend.pdf . Last Accessed 5 Dec 2013.
2. Briefing document for voriconazole (oral and intravenous formulations). Prepared for submission to US Food and Drug Administration, Food and Drugs Advisory Committee. Pfizer; 2001 Oct 4 [cited 2008 Sep 3]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf . Last Accessed 20 Jan 2014.
3. Scholz I, Oberwittler H, Riedel K, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15. doi: 10.1111/j.1365-2125.2009.03534.x .
4. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69(3):222–30. doi: 10.1111/j.1365-2125.2009.03578.x .
5. Hussaini T, Ruping M, Farowski F, Vehreschild J, Cornely O. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy. 2011;31(2):214–25. doi: 10.1592/phco.31.2.214 .
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献